US2012121710A1PendingUtilityA1

Mucosal Immunization

42
Assignee: HERBST-KRALOVETZ MELISSAPriority: Mar 27, 2009Filed: Mar 26, 2010Published: May 17, 2012
Est. expiryMar 27, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:Melissa Herbst-KralovetzCharles J. ArntzenDaniel Tuse
A61K 2039/543A61P 31/00A61K 39/39A61K 2039/5258A61K 39/12A61P 31/14A61K 39/125C12N 2770/16034A61K 2039/5555A61P 31/12A61P 31/20A61P 37/04A61P 31/16
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for eliciting an immune response to an antigen are disclosed. In certain aspects, these methods concern eliciting an immune response in a subject by administering to the mucosa of the subject a composition comprising a virus-like particle (“VLP”) and Murabutide.

Claims

exact text as granted — not AI-modified
1 . A method of eliciting an immune response in a subject comprising contacting a mucosal surface of the subject with an antigen and a NOD agonist, wherein an immune response to the antigen is elicited in the subject. 
     
     
         2 . The method of  claim 1 , wherein the antigen is a virus-like particle (VLP). 
     
     
         3 . The method of  claim 1 , wherein the VLP is derived from a norovirus, calicivirus, hepatitis virus, papilloma virus, or influenza virus. 
     
     
         4 . The method of  claim 1 , wherein the NOD agonist is a muramyl dipeptide derivative. 
     
     
         5 . The method of  claim 4 , wherein the muramyl dipeptide derivative is N-Acetyl-muramyl-L-Alanyl-D-Glutamin-n-butyl-ester (“Murabutide”). 
     
     
         6 . The method of  claim 1 , wherein the antigen and the adjuvant are combined in a single composition. 
     
     
         7 . The method of  claim 1 , wherein the antigen and the adjuvant are in separate compositions. 
     
     
         8 . The method of  claim 6 , wherein the composition comprises a carrier. 
     
     
         9 . The method of  claim 8 , wherein the carrier is a mucoadhesive. 
     
     
         10 . The method of  claim 8 , wherein the mucoadhesive is derived from Aloe vera polyshaccharides. 
     
     
         11 . The method of  claim 6 , wherein the NOD agonist is conjugated to or encapsulated within the VLP structure to form a VLP/NOD agonist complex. 
     
     
         12 . The method of  claim 1 , further comprising contacting the mucosal surface of the subject with a TLR agonist. 
     
     
         13 . The method of  claim 12 , wherein the TLR agonist is a pattern recognition receptor (PRR). 
     
     
         14 . A method of treating a viral disease, comprising administering to a mucosal surface of a subject a viral antigen and a NOD agonist, wherein the viral disease is treated. 
     
     
         15 . The method of  claim 14 , wherein the viral disease is treated prophylactically. 
     
     
         16 . The method of  claim 14 , wherein the viral disease is treated therapeutically. 
     
     
         17 . The method of  claim 14 , wherein the antigen is a virus-like particle (VLP). 
     
     
         18 . The method of  claim 17 , where the VLP is derived from a calicivirus, hepatitis virus, or influenza virus. 
     
     
         19 . The method of  claim 14 , further comprising administering to the mucosal surface of the subject a TLR agonist. 
     
     
         20 . The method of  claim 19 , wherein the TLR agonist is a CpG DNA, gardiquimod, or resiquimod. 
     
     
         21 . The method of  claim 14 , wherein the NOD agonist is a muramyl dipeptide derivative. 
     
     
         22 . The method of  claim 21 , wherein the muramyl dipeptide derivative is N-Acetyl-muramyl-L-Alanyl-D-Glutamin-n-butyl-ester (“Murabutide”). 
     
     
         23 . The method of  claim 5 , wherein the Murabutide is administered at the mucosal surface at a level of 1 to 1,000 micrograms per dose. 
     
     
         24 . The method of  claim 23 , wherein the Murabutide is administered at the mucosal surface at a level of 10 to 500 micrograms per dose. 
     
     
         25 . The method of  claim 24 , wherein the Murabutide is administered at the mucosal surface at a level of 10 to 250 micrograms per dose. 
     
     
         26 . A composition comprising an antigen, a NOD agonist, and a mucoadhesive. 
     
     
         27 . The composition of  claim 26 , wherein the antigen is a virus-like particle (VLP). 
     
     
         28 . The composition of  claim 27 , wherein the VLP is derived from a norovirus, calicivirus, hepatitis virus, papilloma virus, or influenza virus. 
     
     
         29 . The composition of  claim 26 , wherein the NOD agonist is a muramyl dipeptide derivative. 
     
     
         30 . The composition of  claim 29 , wherein the muramyl dipeptide derivative is N-Acetyl-muramyl-L-Alanyl-D-Glutamin-n-butyl-ester (“Murabutide”). 
     
     
         31 . The composition of  claim 26 , wherein the mucoadhesive is derived from Aloe vera polyshaccharides. 
     
     
         32 . The composition of  claim 27 , wherein the NOD agonist is conjugated to or encapsulated within the VLP structure to form a VLP/NOD agonist complex. 
     
     
         33 . The composition of  claim 26 , wherein the composition is formulated to contain 1 to 1,000 micrograms of the NOD agonist per dose. 
     
     
         34 . The composition of  claim 26 , further comprising a TLR agonist.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.